The direct renin inhibitor aliskiren, added to standard therapy with renin-angiotensin system blockade, in patients with type 2 diabetes who are at risk for cardiovascular and renal adverse events was not useful at lowering these events and may even be harmful, according to an online study published in the New England Journal of Medicine.
FDA Approves Combination Therapy for Pulmonary Arterial Hypertension
March 25th 2024J&J’s Opsynvi is single-tablet combination of macitentan, an endothelin receptor antagonist, and tadalafil, a PDE5 inhibitor. It will be priced on parity with Opsumit, which is also a J&J product to treat patients with PAH.